Limitations, agreements, and source contact

Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma · Source last updated 2020-08-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

false

restriction Type

LTE60

restrictive Agreement

true

limitations And Caveats

description

Decimal places were automatically truncated if last decimal equals zero.

point Of Contact

email

clinical-trials-contact@bayer.com

organization

Bayer AG

title

Therapeutic Area Head

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice